Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,412
-30.13%
|
$2,002,380
$115.2 P/Share
|
|
Aug 05
2024
|
Chirfi Guindo Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,901
+38.97%
|
$4,243,615
$115.2 P/Share
|
|
May 04
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
302
-6.38%
|
$38,354
$127.51 P/Share
|
|
May 04
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
612
+11.46%
|
$77,724
$127.51 P/Share
|
|
May 04
2024
|
Michael A Klobuchar EVP - Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
437
-1.82%
|
$55,499
$127.51 P/Share
|
|
May 04
2024
|
Michael A Klobuchar EVP - Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
887
+3.56%
|
$112,649
$127.51 P/Share
|
|
May 04
2024
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Payment of exercise price or tax liability
|
Direct |
13,360
-8.16%
|
$1,696,720
$127.51 P/Share
|
|
May 04
2024
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
27,126
+14.21%
|
$3,445,002
$127.51 P/Share
|
|
May 04
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Payment of exercise price or tax liability
|
Direct |
450
-1.85%
|
$57,150
$127.51 P/Share
|
|
May 04
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
912
+3.62%
|
$115,824
$127.51 P/Share
|
|
May 03
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
845
-9.98%
|
$108,160
$128.26 P/Share
|
|
May 03
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
2,046
+18.8%
|
$261,888
$128.26 P/Share
|
|
May 02
2024
|
Joseph Romanelli President, Human Health Int?l |
SELL
Payment of exercise price or tax liability
|
Direct |
1,115
-5.11%
|
$142,720
$128.8 P/Share
|
|
May 02
2024
|
Joseph Romanelli President, Human Health Int?l |
BUY
Exercise of conversion of derivative security
|
Direct |
2,262
+9.39%
|
$289,536
$128.8 P/Share
|
|
May 02
2024
|
Dalton Smart SVP Fin. - Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
131
-4.3%
|
$16,768
$128.8 P/Share
|
|
May 02
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
381
+11.11%
|
$48,768
$128.8 P/Share
|
|
Feb 14
2024
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
85,021
-19.62%
|
$10,627,625
$125.4 P/Share
|
|
Feb 14
2024
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
85,021
+16.4%
|
$6,206,533
$73.73 P/Share
|
|
Feb 14
2024
|
Caroline Litchfield EVP & CFO |
SELL
Open market or private sale
|
Direct |
38,291
-42.93%
|
$4,786,375
$125.5 P/Share
|
|
Feb 14
2024
|
Caroline Litchfield EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,291
+30.03%
|
$2,220,878
$58.08 P/Share
|
|
Feb 13
2024
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
150,000
-15.9%
|
$18,900,000
$126.06 P/Share
|
|
Feb 13
2024
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+13.75%
|
$11,100,000
$74.55 P/Share
|
|
Feb 13
2024
|
Joseph Romanelli President, Human Health Int?l |
SELL
Open market or private sale
|
Direct |
1,000
-4.86%
|
$124,000
$124.89 P/Share
|
|
Feb 09
2024
|
Dean Y Li Executive VP & President, MRL |
SELL
Open market or private sale
|
Direct |
14,702
-24.12%
|
$1,837,750
$125.5 P/Share
|
|
Feb 09
2024
|
Dean Y Li Executive VP & President, MRL |
BUY
Exercise of conversion of derivative security
|
Direct |
14,702
+19.44%
|
$911,524
$62.07 P/Share
|
|
Feb 07
2024
|
David Michael Williams EVP,Chief Info&Digital Officer |
SELL
Open market or private sale
|
Direct |
1,451
-6.82%
|
$184,277
$127.57 P/Share
|
|
Feb 02
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Open market or private sale
|
Direct |
18,959
-44.84%
|
$2,407,793
$127.17 P/Share
|
|
Feb 02
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
20,937
+16.84%
|
$1,633,086
$78.73 P/Share
|
|
Feb 02
2024
|
Jennifer Zachary EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
49,499
-63.01%
|
$6,236,874
$126.97 P/Share
|
|
Feb 02
2024
|
Jennifer Zachary EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,417
+19.82%
|
$1,689,279
$87.1 P/Share
|
|
Feb 02
2024
|
Steven Mizell EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
50,694
-68.22%
|
$6,387,444
$126.65 P/Share
|
|
Feb 02
2024
|
Steven Mizell EVP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,994
+16.06%
|
$2,375,568
$72.22 P/Share
|
|
Jan 22
2024
|
David Michael Williams EVP,Chief Info&Digital Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,196
+32.41%
|
$1,213,324
$119.43 P/Share
|
|
Jan 22
2024
|
Dalton Smart SVP Fin. - Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,661
+49.94%
|
$316,659
$119.43 P/Share
|
|
Jan 22
2024
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Grant, award, or other acquisition
|
Direct |
3,133
+12.8%
|
$372,827
$119.43 P/Share
|
|
Jan 22
2024
|
Dean Y Li Executive VP & President, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
25,760
+35.78%
|
$3,065,440
$119.43 P/Share
|
|
Jan 22
2024
|
Jennifer Zachary EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
23,298
+28.26%
|
$2,772,462
$119.43 P/Share
|
|
Jan 22
2024
|
Steven Mizell EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,384
+30.79%
|
$2,187,696
$119.43 P/Share
|
|
Jan 22
2024
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
26,716
+50.0%
|
$3,179,204
$119.43 P/Share
|
|
Jan 22
2024
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
23,296
+14.64%
|
$2,772,224
$119.43 P/Share
|
|
Jan 22
2024
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
76,510
+18.01%
|
$9,104,690
$119.43 P/Share
|
|
Jan 22
2024
|
Michael A Klobuchar EVP - Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,896
+14.43%
|
$463,624
$119.43 P/Share
|
|
Jan 22
2024
|
Caroline Litchfield EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
19,208
+27.39%
|
$2,285,752
$119.43 P/Share
|
|
Nov 09
2023
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Open market or private sale
|
Direct |
2,081
-10.27%
|
$212,262
$102.38 P/Share
|
|
Nov 08
2023
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
43,823
-28.17%
|
$4,601,415
$105.03 P/Share
|
|
Oct 30
2023
|
Johannes Jacobus Oosthuizen President, U.S. Market |
SELL
Payment of exercise price or tax liability
|
Direct |
451
-2.18%
|
$46,002
$102.82 P/Share
|
|
Oct 30
2023
|
Johannes Jacobus Oosthuizen President, U.S. Market |
BUY
Exercise of conversion of derivative security
|
Direct |
915
+4.23%
|
$93,330
$102.82 P/Share
|
|
Aug 14
2023
|
Steven Mizell EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
4,250
-15.63%
|
$463,250
$109.01 P/Share
|
|
Aug 03
2023
|
Chirfi Guindo Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,989
-46.92%
|
$1,888,845
$105.7 P/Share
|
|
Aug 03
2023
|
Chirfi Guindo Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,901
+49.04%
|
$3,874,605
$105.7 P/Share
|